Barbara Ann Karmanos Cancer Institute
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Barbara Ann Karmanos Cancer Institute sits in the top decile of US sponsors by registered trial count (#202 of 15,742 sponsors by registered trial count).
Barbara Ann Karmanos Cancer Institute: 139 sponsored US clinical trials, 16 recruiting.
Barbara Ann Karmanos Cancer Institute sponsors 139 registered US clinical trials on ClinicalTrials.gov, 16 of them currently recruiting, and 100 completed. 1 of these trials are in Phase 3-4 (later-stage) and 99 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Prostate Cancer, with 4 trials.
Top-decile sponsor footprint
Barbara Ann Karmanos Cancer Institute ranks in the top decile of sponsors by registered trial count (#202 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
100 of 120 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (83.3%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
139 total, page 3 of 3
Combination Chemotherapy Followed By Autologous Stem Cell Transplant, and White Blood Cell Infusions in Treating Patients With Non-Hodgkin's Lymphoma
NCT00244946
Gemcitabine Hydrochloride and Genistein in Treating Women With Stage IV Breast Cancer
NCT00244933
Ph II Long Term/Low Dose Xeloda in Head and Neck Squamous Cell Carcinoma After Surgery, Radiation & or Chemo
NCT00258310
Capecitabine and Docetaxel in Treating Patients With Metastatic Prostate Cancer
NCT00258284
Zileuton in Preventing Lung Cancer in Patients With Bronchial Dysplasia
NCT00056004
Imatinib Mesylate and 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Chronic Myelogenous Leukemia
NCT00066326
Gefitinib and Celecoxib in Treating Patients With Refractory Non-Small Cell Lung Cancer
NCT00068653
Isoflavones and Radiation Therapy in Treating Patients With Localized Prostate Cancer
NCT00243048
Imatinib Mesylate After Irinotecan and Cisplatin in Treating Patients With Extensive-Stage Small Cell Lung Cancer
NCT00248482
Celecoxib, Capecitabine, and Irinotecan in Treating Patients With Recurrent or Metastatic Colorectal Cancer
NCT00258232
XK469 in Treating Patients With Advanced Solid Tumors
NCT00028548
Soy Isoflavones in Treating Patients Who Are Undergoing Radical Prostatectomy for Stage I or Stage II Adenocarcinoma of the Prostate
NCT00078923
Celecoxib and Docetaxel in Treating Patients With Non-Small Cell Lung Cancer
NCT00030407
Biological Therapy in Treating Women With Stage IV Breast Cancer
NCT00027807
Celecoxib and Docetaxel in Treating Patients With Advanced Non-Small Cell Lung Cancer
NCT00030420
Proteases in Patients With Prostate Cancer That Has Spread to the Bone
NCT00899665
Flavopiridol and Docetaxel in Treating Patients With Advanced Solid Tumors
NCT00016185
PEG-Interferon Alfa-2b and Thalidomide in Treating Patients With Recurrent or Metastatic Melanoma
NCT00238329
Chemotherapy in Treating Patients With Advanced Kidney Cancer
NCT00011973
Rebeccamycin Analog in Treating Patients With Advanced Kidney Cancer
NCT00005027
Bryostatin 1 Plus Gemcitabine in Treating Patients With Advanced Cancer
NCT00004144
Bryostatin 1 in Treating Patients With Recurrent or Refractory Hodgkin's Disease
NCT00003936
Combination Chemotherapy in Treating Patients With Stage III or Stage IV Pancreatic Cancer That Cannot Be Removed by Surgery
NCT00004003
Dolastatin 10 in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Previous Hormone Therapy
NCT00003626
Chemotherapy and Vaccine Therapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation and Interleukin-2 in Treating Patients With Recurrent or Refractory Brain Cancer
NCT00014573
Bryostatin 1 in Treating Patients With Myelodysplastic Syndrome
NCT00003171
Combination Chemotherapy In Treating Patients With Advanced Cancer
NCT00003925
Fenretinide in Treating Patients With Solid Tumors
NCT00003250
Bryostatin 1 Plus Cladribine in Treating Patients With Relapsed Chronic Lymphocytic Leukemia
NCT00003174
Bryostatin 1 in Treating Patients With Metastatic Colorectal Cancer
NCT00003220
Biological Therapy Following Surgery and Radiation Therapy in Treating Patients With Primary or Recurrent Astrocytoma or Oligodendroglioma
NCT00004024
Biological Therapy Following Surgery in Treating Patients With Stage III or Stage IV Melanoma
NCT00004022
KRN5500 in Treating Patients With Metastatic Solid Tumors
NCT00002923
Bryostatin 1 in Treating Patients With Relapsed Multiple Myeloma
NCT00002907
Bryostatin 1 in Treating Patients With Relapsed Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia
NCT00002908
Pyrazoloacridine in Treating Patients With Advanced Non-small Cell Lung Cancer
NCT00002656
Pyrazoloacridine in Treating Women With Metastatic Breast Cancer
NCT00002585
Chemotherapy Plus Bone Marrow Transplantation in Treating Patients With Refractory Non-Hodgkin's Lymphoma, Hodgkin's Disease, or Multiple Myeloma
NCT00002552
Chemotherapy and Bone Marrow Transplantation in Treating Patients Acute Myeloid With Leukemia or Myelodysplastic Syndrome
NCT00002547
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 33 |
| Phase 2 | 66 |
| Phase 3 | 1 |
What is open in the Barbara Ann Karmanos Cancer Institute pipeline
16 recruiting of 139 indexed (12% open); 100 completed (72%).
Phase mix: 1 late (III/IV) vs 99 early (I/II) (early-phase heavy).
Top condition: Prostate Cancer (4 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Barbara Ann Karmanos Cancer Institute: open-pipeline peers nationwide
Peers matched on 139 registered trials and 12% open enrollment, not the therapeutic-area sidebar.
Barbara Ann Karmanos Cancer Institute sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 139 trials (± recruiting share)
- Centers for Disease Control and Prevention · 139 trials · 2% recruiting
- Mclean Hospital · 140 trials · 19% recruiting
- Shirley Ryan AbilityLab · 138 trials · 26% recruiting
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University · 138 trials · 3% recruiting
Sponsors near 12% open enrollment (± trial volume)
- Abbott Diabetes Care · 12% recruiting · 26 trials
- Medtronic Vascular · 12% recruiting · 26 trials
- Midwest Center for Metabolic and Cardiovascular Research · 12% recruiting · 26 trials
- VA Connecticut Healthcare System · 12% recruiting · 26 trials
Related
What to do with this Barbara Ann Karmanos Cancer Institute page
139 registered trials is a research-attention snapshot, not an endorsement of Barbara Ann Karmanos Cancer Institute or any single study.
- 16 of Barbara Ann Karmanos Cancer Institute's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Prostate Cancer is the condition Barbara Ann Karmanos Cancer Institute studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Prostate Cancer trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Barbara Ann Karmanos Cancer Institute pipeline card: 139 registered trials from official public datasets.Report a data error.